Cargando…

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma

BACKGROUND: Pleural malignant mesothelioma (MM) is a deadly tumour predominantly associated with asbestos exposure. A reliable diagnostic and prognostic marker for MM will significantly enhance clinical care and is an area of intense research. Soluble mesothelin is the most studied and an FDA-approv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creaney, Jenette, Dick, Ian M, Meniawy, Tarek M, Leong, Su Lyn, Leon, Justine S, Demelker, Yvonne, Segal, Amanda, (Bill) Musk, A W, Lee, Y C Gary, Skates, Steven J, Nowak, Anna K, Robinson, Bruce W S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Biomarkers of Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174124/ https://www.ncbi.nlm.nih.gov/pubmed/25037982 http://dx.doi.org/10.1136/thoraxjnl-2014-205205

Ejemplares similares

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Discovery of new biomarkers for malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2015)

Auto-Antibodies to β-F1-ATPase and Vimentin in Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2011)

Fibulin1 and mesothelin expressions in pancreas ductal adenocarcinoma
por: Aksoy, Asude, et al.
Publicado: (2023)

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol
por: Hoon, Siao Nge, et al.
Publicado: (2020)

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
por: Meniawy, T M, et al.
Publicado: (2013)

How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies
por: Robinson, Bruce W.S., et al.
Publicado: (2022)

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
por: Greening, David W., et al.
Publicado: (2016)

Response to comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'
por: Meniawy, T M, et al.
Publicado: (2014)

Calretinin as a blood-based biomarker for mesothelioma
por: Johnen, Georg, et al.
Publicado: (2017)

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019)

Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
por: Robinson, Cleo, et al.
Publicado: (2015)

A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
por: Bydder, S, et al.
Publicado: (2004)

Immune marker expression of irradiated mesothelioma cell lines
por: Chang, Faith, et al.
Publicado: (2022)

Hyaluronic acid in viscous malignant mesothelioma pleural effusion
por: Cheah, Hui Min, et al.
Publicado: (2020)

Metabolomics of World Trade Center-Lung Injury: a machine learning approach
por: Crowley, George, et al.
Publicado: (2018)

The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease
por: Khan, Fasihul, et al.
Publicado: (2019)

Non-invasive testing for liver pathology in alpha-1 antitrypsin deficiency
por: Abbas, Syed Hamza, et al.
Publicado: (2020)

Performance evaluation of human cough annotators: optimal metrics and sex differences
por: Sanchez-Olivieri, Isabel, et al.
Publicado: (2023)

p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
por: Creaney, J, et al.
Publicado: (2001)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma
por: Sneddon, Sophie, et al.
Publicado: (2017)

Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma
por: Kovac, Viljem, et al.
Publicado: (2015)

What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination
por: Redwood, Alec J., et al.
Publicado: (2022)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
por: Nowak, A K, et al.
Publicado: (2002)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma
por: Sneddon, Sophie, et al.
Publicado: (2019)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
por: Chee, Jonathan, et al.
Publicado: (2018)

The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach
por: Hoes, Martijn F., et al.
Publicado: (2019)

Profile of soluble factors in pleural effusions predict prognosis in mesothelioma
por: Dick, I.M., et al.
Publicado: (2022)

Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review
por: Henkens, Michiel T.H.M., et al.
Publicado: (2020)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

A combined bioinformatics, experimental and clinical approach to identify novel cardiac‐specific heart failure biomarkers: is Dickkopf‐3 (DKK3) a possible candidate?
por: Piek, Arnold, et al.
Publicado: (2020)

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma
por: de Fonseka, Duneesha, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5oqrkvtao6fu5vcjrsn566rrr9